Shandong Xiwang Pharmaceutical Co., Ltd.: Driving High-Quality Development Through Technological Innovation

Shandong Xiwang Pharmaceutical Co., Ltd. was awarded the title of "Top Ten Innovative Enterprises in China's Pharmaceutical Industry" at the 2025 China Pharmaceutical Innovation and Development Conference, a high recognition of the company's technological innovation achievements in the pharmaceutical field. As a core enterprise of the Xiwang Group's pharmaceutical sector, Shandong Xiwang Pharmaceutical has always adhered to the development philosophy of "innovation-driven, quality-first," achieving a series of significant breakthroughs in the research and development and production of active pharmaceutical ingredients (APIs).

Shandong Xiwang Pharmaceutical possesses a national-level enterprise technology center and a postdoctoral research station, establishing a comprehensive innovation system. Its annual R&D investment accounts for over 8% of its sales revenue. In recent years, the company has achieved numerous innovative results in the fields of glucose derivatives and pharmaceutical excipients. Among them, the "High-purity Anhydrous Glucose Preparation Technology" won the first prize of Shandong Provincial Science and Technology Progress Award, and the "Pharmaceutical Maltodextrin Industrialization Project" was included in the National Key New Product Plan.

In terms of quality control, Shandong Xiwang Pharmaceutical Co., Ltd. has established a full-chain quality traceability system and has passed ISO9001, ISO14001, ISO45001, HACCP, and GMP certifications, achieving internationally advanced product quality levels. The company's glucose raw materials, fructose, and other products have passed multiple authoritative international certifications, including the US FDA, EU CEP, and Japanese PMDA, and are exported to more than 60 countries and regions worldwide.

The chairman of Shandong Xiwang Pharmaceutical Co., Ltd. stated, "Shandong Xiwang Pharmaceutical Co., Ltd. will take this award as an opportunity to continue increasing R&D investment, accelerate the transformation of innovative achievements, and contribute Xiwang's strength to the high-quality development of the pharmaceutical industry." In the future, the company plans to expand into the biopharmaceutical field, developing innovative drugs with independent intellectual property rights, and achieving industrial upgrading from raw materials to finished products.

CONTACT INFORMATION

Website:https://www.xiwang-pharmaceutical.com/

Phone:+8615371019725

Email:sales7@boxa-chem.com